Despite the successes of Viagra TM , the quest for new and better therapy for erectile dysfunction (ED) continues. In a recent survey of the ®rst 220 patients placed on Viagra TM at our institution, 101 (46%) quit taking the drug: 76% of those who quit were not satis®ed with the results. Patients clearly want an ef®cacious, safe, convenient medication with rapid onset. To meet these consumer demands, numerous new therapies are being developed. These include new oral medications, new intracavernosal pharmacotherapies, new delivery systems (such as novel intracorporal injectors and transdermal agents) and combination therapies. What is known about these new medications and delivery systems will be presented. Hopefully, from these innovations will come therapies that will improve the overall success and acceptance of treatment for ED. Since it is unlikely that any single agent will ever provide a solution for all men with ED, an expanded armamentarium of treatment options will greatly enhance the chances that any given man will be able to ®nd a therapy that is both acceptable and appropriate to him.
Introduction
A recent review of patients at the University of Minnesota who were placed on the oral medication, Viagra TM , revealed that 46% quit taking the medication, with the primary reason for quitting being lack of ef®cacy. Clearly, the perfect treatment for erectile dysfunction (ED) does not exist. Patients desire treatment that is ef®cacious, safe and without side effects, easily administered, and with a rapid onset of action. To meet these expectations, numerous treatments for ED are in various stages of development. New therapies under study include oral medications, injectables, urethral suppositories, and new modes of delivery such as topical therapy. We will review most of the therapies that are currently under some phase of human investigation but have not yet been submitted to the FDA for review in a New Drug Application (NDA).
New oral therapies

IC351 (Eli Lilly)
This is a potent oral PDE-5 inhibitor. A double blind, placebo controlled, single crossover study of 44 patients with mild to moderate ED was reported. 1 Rigidity and duration of erections to visual stimulation were assessed using a RigiScan TM . Duration of erection measured at the base of the penis increased from baseline by 1.43 AE 6.34 minutes (mean AE STD) for placebo and 9.43 AE 12.66 minutes for IC351 (P`0.001). There was a signi®cant increase in rigidity and 38 (86%) patients reported enhanced erections on IC351 compared to 18 (44%) patients on placebo (P`0.001). IC351 is thought to be a more selective molecule for PDE-5 which may translate into an improved side effect pro®le. Eli Lilly started Phase III studies with IC351 in the fall of 1999.
Bay 38-9456 (Bayer)
This is a PDE-5 inhibitor that appears to be more speci®c and potent on a milligram basis than sildena®l citrate. Phase II clinical trials are underway and will be analyzed over the next few months before a decision is made whether to proceed with Phase III trials.
UK-357903 and UK-343664 (P®zer)
These compounds are both PDE-5 inhibitors being evaluated by P®zer. UK-357903 is well tolerated and comparable in ef®cacy at half the dose to sildena®l citrate. UK-343664 has been shown to have 100-fold greater selectivity for PDE-5 over PDE-6. They are both being evaluated in Phase II trials in Europe.
BMS-223131 (Bristol-Myers Squibb)
This oral potassium channel (maxi-K) opener is currently being evaluated in Phase IIa studies in the United States. This company previously tested an oral endothelin receptor antagonist, BMS-193884, but the results showed no ef®cacy for inducing erections. No further clinical activity is ongoing with BMS-193884.
BMS-341400 (Bristol-Myers Squibb)
An IND has recently been ®led with the FDA for evaluating BMS-341400, a PDE-5 inhibitor.
Didesmethyl sibutramine (S-DDMS) (Sepracor)
Sibutramine, an anorectic agent approved for weight loss, is relatively inactive in vitro as a monoamine reuptake inhibitor, however, it is metabolized primarily to four active metabolites: (R)-Ndesmethyl sibutramine, (R)-DMS; (S)-N-desmethyl sibutramine, (S)-DMS; (R)-N,N-didesmethyl sibutramine, (R)-DDMS; and (S)-N,N-didesmethyl sibutramine, (S)-DDMS. The S isomer of the secondary metabolite of sibutramine, (S-DDMS), has been shown to be a potent norepinephrine and dopamine reuptake inhibitor. Sepracor is investigating S-DDMS as an oral agent for treatment of ED and will begin Phase I studies this fall. 
New intracavernosal (IC) therapies
PNU-83757 (Pharmacia and Upjohn)
PNU-83757 is a potassium channel opener. In a recent dosing study of patients with vasculogenic impotence, the lowest dose that could enable a patient to achieve a full erection was 10 mcg IC. 2 Of ®ve patients who received 80 mcg IC, two had full erections and three had partial responses. There were no signi®cant side effects reported. Pharmacia and Upjohn considered PNU-83757 a potential successor to Caverject 1 . Unfortunately, results to date suggest the dose-response to PNU-83757 is not as predictable and ef®cacy is below target expectations. Clinical activity with PNU-83757 has been suspended while the company considers other candidates to elicit erections, including dopaminergic drugs.
Senetek is investigating combination IC therapy with vasoactive intestinal polypeptide (VIP) and phentolamine using a patented`user friendly' autoinjector. The injector was designed to improve patient acceptance: it is disposable, has a small needle (29 gauge) that is not visible until injection, injects only after the needle is 1.0 cm deep, and has a pre-®lled single dose. In a recent multi-institutional study of 236 men with primarily organic impotence, 82% had an erection satisfactory for penetration on a dose of either 25 mcg VIP plus 1.0 or 2.0 mg phentolamine. 
MJ-7 Medijector (Medi-Ject)
This is a needle free injector using high pressure to force¯uid through tissue. The MJ-7 Medijector is currently being used commercially to deliver insulin and growth hormone subcutaneously. Pre-clinical studies are in progress where alprostadil is injected intracorporally. An IND has not yet been ®led.
Nitric oxide agents (NitroMed)
NitroMed is developing a number of injectable nitric oxide (NO) derivatives. NO-glutathione (NMI 102) is a nitric oxide donor that is being combined with prostaglandin E1. In vitro studies using human corporal tissue suggests NMI 102 signi®cantly improves the potency of PGE 1 . NMI 102 is being positioned as causing less discomfort than PGE 1 and Phase I studies with NMI 102 will be completed this year. NitroMed is also studying a variety of nitrosylated a-adrenergic receptor antagonists. These nitrosylated compounds release a NO donor and the parent molecule that antagonizes adrenergic receptors, thus having the dual function of both inducing corporal smooth muscle relaxation while inhibiting sympathetic tone. 4 These molecules did not induce pain when tested in a paw ± lick model in mice. 4 NitroMed will enter Phase I studies with a nitrosylated compound in 2000.
Other therapies
Topiglan (alprostadil 1% SEPA gel) is a topical agent applied to the glans penis. SEPA (Soft Enhancer of Percutaneous Absorption) is a transdermal enhancer that alters the¯uidity of lipids in the stratum corneum and increases penetration of the alprostadil. A Phase II placebo-controlled double blind in-of®ce study of 60 patients with moderate to severe ED was performed to assess Topiglan TM . 5 In response to erotic stimuli, 12 of 31 patients (39%) given Topiglan TM had an erection judged suf®cient for vaginal penetration compared to two of 29 (7%) receiving placebo (P 0.003). Application site reactions (primarily burning or warmth) occurred in 44% of those receiving drug compared to 30% receiving placebo, not statistically different (P 0.302). All side-effects were described as minor or mild.
Alibra (Vivus)
Alibra is transurethral therapy using a combination of alprostadil (125 mcg) and the a1 blocker prazosin (500 mcg). Phase III studies have been completed. Alibra has similar ef®cacy to MUSE but only one dose is necessary which makes titration of the drug unnecessary. A New Drug Application was ®led with the FDA in December, 1999.
Alprox-TD (NEXMED)
Alprox-TD is a topical cream combining alprostadil with the transdermal delivery enhancer, NexACT. The company reports a 75% ef®cacy rate, as determined by the International Index of Erectile Dysfunction (IIEF) and the pre-dose Sexual Encounter Pro®le (SEP) in 56 patients with mild to moderate impotency in a Phase III study conducted in China. NEXMED is currently conducting Phase II studies in the US, and expects to begin Phase III studies later this year.
Melanotan II (Palatin Technologies)
Melanotan II, a synthetic analog of alpha melanocyte stimulating hormone, is currently delivered subcutaneously. Results of studies with Melanotan II are presented elsewhere in this supplement. 6 The peptide initiates erections in men with psychogenic and organic ED. 7, 8 Side effects include nausea and yawning. Melanotan II has been licensed to Palatin Technologies and Phase IaII studies are ongoing.
Discussion
As can be seen, there are many new therapies under various stages of development: eight are oral medications (Table 1) , ®ve are intracavernosal medications or delivery systems (Table 2) , and ®ve are other therapies (Table 3 ). In addition to the development of new medications, new delivery systems are being proposed. There are two companies currently working on transdermal systems (Macrochem Corp. and NEXMED), two on new injectors for intracavernosal therapy (Medi-Ject and SenetekPLC), and undoubtedly, intranasal therapy is in the preliminary stages of investigation. Even within a particular mechanism of action, such as PDE-5 inhibitors, there are many new drugs that are being developed. Though this may seem like pointless competition, there is likely to be a role for many of these drugs as some of them may have a faster onset of action than sildena®l citrate while others may be more selective thus increasing ef®cacy and decreasing side effects.
Our enthusiasm needs to be tempered, as some of these medications or delivery mechanisms may not make it to the US marketplace. For example, phentolamine is under scrutiny by the FDA because it caused a brown fatty hyperplasia in some rats during the oral carcinogenicity studies. This, in turn, affects the development of other possible future treatments, such as INVICORP (Senetek PLC ), which includes phentolamine as part of its combination intracavernosal therapy.
There are other radical treatments in the laboratory stage of investigation that have not yet advanced to human studies, such as gene therapy. 9 Another example is intranasal apomorphine, but there is not enough information available on which to comment at this time. Finally, combination therapy is likely to be a common treatment strategy in the future. The bene®t of combination therapy is synergistic action, which has the potential for outcomes better than either treatment alone at lower doses, resulting in fewer side effects. This hypothesis is supported by several recent studies of combination therapy. 10,11
Conclusion
There are many new drugs and delivery systems that are under various stages of investigation. Eight new oral drugs are being studied, ®ve of which are PDE-5 inhibitors. New delivery systems, such as drug delivery by topical enhancers, new intravernosal injectors, and even intranasal therapy are being studied. Some of these drugs and delivery systems will ultimately make it into the market place, whereas others will not show any particular bene®t or have undesirable side-effects and not make it. There is not likely to be any one drug or delivery system which can meet the needs of all patients with ED. In fact, combination therapy looks very promising since its synergistic action may result in greater ef®cacy with lower side effects. Our heterogeneous patient population with its various etiologies of ED and disparate demands (eg rapid onset of action vs ef®cacy) ensures that having access to a wide range of medications and delivery systems will be desirable. Thanks to the efforts of independent investigators and the pharmaceutical industry, the future appears promising for many new treatments. This should lead to greater satisfaction amongst our 
